Comparing Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization Methods to Determine the HER2/neu Status in Primary Breast Carcinoma using Tissue Microarray-Reference-Cited by-同舟云学术

Comparing Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization Methods to Determine the HER2/neu Status in Primary Breast Carcinoma using Tissue Microarray

Published:2003-09 Issue:9 Volume:16 Page:937-943
ISSN:0893-3952
Container-title:Modern Pathology
language:
Short-container-title:Mod Pathol

Author:

Park Kyeongmee,Kim Jungyeon,Lim Sungjig,Han Sehwan,Lee Jung Young

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Reference22 articles.

1. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.

2. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

3. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

4. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.

5. erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy;RadioGraphics;2023-02-01

2. Utilizing multiplex fluor LAMPs to illuminate multiple gene expressions in situ;PLOS ONE;2019-10-04

3. Transferred-tissue Microarray for Fluorescence In Situ Hybridization Test for Human Epidermal Growth Factor Receptor 2 in Breast Cancer;Applied Immunohistochemistry & Molecular Morphology;2019-01-16

4. TheHER2CISH pharmDx™Kit in the assessment of breast cancer patients for anti-HER2 treatment;Expert Review of Molecular Diagnostics;2013-04

5. Comparison of FluorescenceIn SituHybridization and ChromogenicIn SituHybridization for Low and High ThroughputHER2Genetic Testing;International Journal of Breast Cancer;2013